Practical experience with rituximab subcutaneous
CPD Previous     Next

Practical experience with rituximab subcutaneous

Sarah Liptrott Clinical research nurse, European Institute of Oncology, Milan, Italy
Nicola Crosbie Nurse clinician, Derriford Hospital, Plymouth Hospitals NHS Trust
Maris Stella Sugino Nurse clinician, Hospital das Clínicas da FMUSP, São Paulo, Brazil
Renate Bratke Nurse clinician, Technical University Munich, Germany
Maria Mendoza International scientific director, F Hoffmann-La Roche Ltd, Basel, Switzerland
Pakeeza Sayyed Senior clinical scientist, F Hoffmann-La Roche Ltd, Basel, Switzerland

Treatment regimens involving the monoclonal anti-CD20 antibody rituximab are the standard of care for patients with CD20-positive non-Hodgkin lymphoma (NHL). It has conventionally been given by intravenous (IV) infusion, which requires intermittent patient monitoring during administration. A subcutaneous (SC) formulation is also available for the treatment of NHL, which takes less time to administer and could simplify treatment. With the newer formulation available, there is an ongoing need for education and understanding from the patient’s and the healthcare professional’s perspective. The authors review their personal experience of rituximab IV and SC formulations together with data on their safety, and provide an overview of the use of SC formulation in daily nursing practice.

Cancer Nursing Practice. 14, 8,29-37. doi: 10.7748/cnp.14.8.29.s22

Correspondence

sarah.liptrott@ieo.it

Peer review

This article has been subject to double-blind review and checked using antiplagiarism software

Conflict of interest

The production cost and support for third-party writing assistance for this manuscript were provided by F Hoffmann-La Roche Ltd who have checked it for factual accuracy, with editorial control remaining with the journal at all times

Received: 20 March 2015

Accepted: 03 August 2015